Table 1 Patient demographics and baseline clinical characteristics (n = 20)
Variables | Values |
|---|---|
Age at diagnosis (years) | 57.5 ± 9.6 [34–75] |
Sex (male/female) | 6:14 |
Primary tumour site, n (%) | Â |
 Pancreas | 10 (50%) |
 Rectum | 6 (30%) |
 Duodenum | 1 (5%) |
 Stomach | 1 (5%) |
 Kidney | 1 (5%) |
 Unknown | 1 (5%) |
Hepatic metastasis, n (%) | 20 (100%) |
Extrahepatic metastasis, n (%) | 18 (90%) |
 Lymph node | 15 (75%) |
 Bone | 11 (55%) |
 Peritoneal seeding | 3 (15%) |
 Other | 5 (25%) |
Grade, n (%) | Â |
 1 | 1 (5%) |
 2 | 15 (75%) |
 3 | 4 (20%) |
Ki-67, n (%) | Â |
 < 3% | 1 (0.7%) |
 3–20% | 15 (9.5% ± 4.8%) |
 > 20% | 4 (25.3% ± 3.3%) |
Krenning score, n (%) | Â |
 3 | 6 (30%) |
 4 | 14 (70%) |
Site of target lesions, n | 55 |
 Pancreas | 7 |
 Liver | 37 |
 Lymph node | 10 |
 Peritoneal seeding | 1 |
Number of PRRT cycles, n (%) | Â |
 1 | 0 (0%) |
 2 | 2 (10%) |
 3 | 1 (5%) |
 4 | 17 (85%) |
Interval between PRRT cycles (days) | 71 ± 19 [49–151] |